SGIOY - ViiV Healthcare receives European marketing authorization for HIV-1 infection

ViiV Healthcare announces the European Marketing Authorization of Rukobia (fostemsavir) 600mg extended-release tablets, a HIV attachment inhibitor, for use in combination with other antiretroviral ((ARV)) therapies for treatment of adults with multidrug-resistant HIV-1 infection. Fostemsavir, under the brand name Rukobia, was licensed by the FDA on July 2, 2020, and further regulatory applications have been submitted worldwide.ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK), Pfizer (PFE) and Shionogi (SGIOY).

For further details see:

ViiV Healthcare receives European marketing authorization for HIV-1 infection